Zantac Lawsuit Update: MDL & Case Analysis (2026)

‍In re Zantac (Ranitidine) Products Liability Litigation (2020), No. 9:20-md-02924 (S.D. Fla.), drew more than 15,000 federal actions after the JPML transferred cases to the Southern District of Florida in February 2020. GSK's $2.2 billion October 2024 settlement and Delaware Superior Court's April 2026 dismissal of approximately 80,000 pre-December 2025 Delaware cases reshaped the litigation. A parallel federal MDL offers a useful comparison.

This analysis covers the MDL proceedings, Delaware's realignment, settlement architecture, and practice implications for plaintiff and defense counsel. The Eleventh Circuit appeal of Judge Rosenberg's 341-page Daubert order remains the highest-impact pending variable.

NDMA Discovery, Valisure's 2019 Petition, and FDA Withdrawal

The trajectory from FDA approval to market withdrawal spanned nearly four decades, and the regulatory record became the evidentiary battleground for every Zantac lawsuit filed thereafter.

GSK received FDA approval for ranitidine in 1983. The patent expired in 1997, and OTC rights subsequently passed through Pfizer (1998-2006), Boehringer Ingelheim (2006-2017), and Sanofi (2017-2020). On September 13, 2019, Valisure filed a petition reporting NDMA contamination in ranitidine tablets exceeding 3,000,000 ng per tablet across all lots tested.

The FDA's own testing detected lower NDMA levels, a discrepancy attributed to differing laboratory practices and temperatures. By November 2019, the FDA advised manufacturers to limit NDMA levels to 96 nanograms per day. On April 1, 2020, the FDA requested withdrawal of all prescription and OTC ranitidine products, citing evidence that NDMA levels increase under normal storage conditions.

Two later regulatory findings complicated the causation picture:

• September 2020: The European Medicines Agency concluded there was "no evidence of a causal association" between ranitidine therapy and cancer development, though it qualified that any risk would likely be too low to detect through conventional studies.
• Summer 2021: An FDA clinical trial concluded that ranitidine doesn’t increase NDMA under physiological conditions, and the agency indicated it may consider return if stability and acceptable NDMA levels can be demonstrated.

In spring 2021, Sanofi relaunched the brand as Zantac 360°, reformulated with famotidine, an H2-blocker the FDA confirmed does not form NDMA. Brand-name defendants in the resulting litigation included GSK, Sanofi, Pfizer, and Boehringer Ingelheim, along with contract manufacturer Patheon Manufacturing Services.

MDL 2924 and the 341-Page Daubert Order

The federal MDL established the evidentiary framework that later propagated across state forums. On February 6, 2020, the JPML transferred cases before Judge Robin L. Rosenberg.

The procedural sequence that followed set the terms for every subsequent Zantac lawsuit filing:

• July 2021: The court dismissed generic claims on federal preemption grounds, along with retailer and distributor claims. Plaintiffs proceeded against brand-name defendants on five cancer types: bladder, esophageal, gastric, liver, and pancreatic.
• December 6, 2022: Judge Rosenberg issued a 341-page Daubert order (644 F. Supp. 3d 1075) excluding all ten of plaintiffs' general causation experts as methodologically unreliable. The court found that experts could not aggregate various categories of individually unreliable evidence to form a reliable causation theory.
• May 2023: Summary judgment for defendants followed, with Rule 58 final judgment entered in September 2023.
• October 24, 2023: Plaintiffs filed a joint notice of appeal to the Eleventh Circuit.

The Eleventh Circuit appeal, lead docket No. 21-12618, heard oral argument on October 10, 2025, before Judges Adalberto Jordan, Barbara Lagoa, and Virginia Hernandez Covington. The oral argument remains without a decision as of May 2026.

Per JPML statistics dated May 1, 2026, MDL 2924 retains 847 pending actions from 15,018 total historical filings.

Delaware's Reversal Arc and the 8-0 Bellwether Record

After the federal MDL dismissal, plaintiffs migrated to state forums, with the largest concentration in Delaware, where approximately 75,000 cases were filed. The divergence between federal and state expert-admissibility standards drove the most consequential procedural sequence in the litigation.

On May 31, 2024, Delaware Superior Court Judge Vivian Medinilla admitted plaintiffs' general causation experts, applying a "liberal thrust" admissibility standard and framing general causation around NDMA rather than ranitidine itself. The Delaware Supreme Court granted interlocutory review on August 27, 2024.

On July 10, 2025, the Delaware Supreme Court unanimously reversed in In re Zantac (Ranitidine) Litig., No. 255, 2024, 2025 WL 1903760 (Del. July 10, 2025). The en banc court held that:

• DRE 702 must align with FRE 702, including the 2023 amendments
• The "liberal thrust" standard erroneously presumed admissibility
• General causation analysis must focus on the product (ranitidine), not the component (NDMA)

On December 1, 2025, Judge Francis J. Jones denied plaintiffs' motion to supplement expert reports. On April 14, 2026, Judge Jones extended that ruling to all pre-December 2025 filings, dismissing approximately 80,000 cases in a 17-page opinion: "plaintiffs were not entitled to a mulligan in the face of Delaware's clear and existing law on causation that plaintiffs were unable to meet."

Other state forums reached similar conclusions on expert admissibility. In August 2024, a Florida state court excluded plaintiffs' general and specific causation experts in the Wilson prostate cancer case, aligning with the federal MDL on the unreliability of plaintiffs' methodology.

Bellwether trials across state courts reinforced the defense position:

• Valadez (May 2024, Cook County): defense verdict for GSK and Boehringer Ingelheim against a $640 million demand.
• Joiner (August 2024, Illinois): defense verdict for GSK on colorectal cancer claims.
• Russell v. Boehringer Ingelheim Pharmaceuticals, Inc. (November 2024, Alameda County): hung jury on whether Zantac caused the plaintiff's bladder cancer.
• Boehringer Ingelheim accumulated eight consecutive trials without a plaintiff verdict across colorectal, prostate, bladder, and kidney cancer claims.

International parallels reinforced the trend. On May 12, 2023, the British Columbia Supreme Court dismissed a proposed class action on behalf of Canadian ranitidine users in Dussiaume v. Sandoz Canada Inc., 2023 BCSC 795.

The $2.2B GSK Settlement and Boehringer's Holdout Strategy

The settlement architecture reflects different strategic calculations by co-defendants facing identical causation challenges. Timing, forum, and evidentiary posture mattered as much as the underlying merits, a dynamic visible across parallel MDL litigation.

• GSK announced its state court settlement on October 9, 2024, in an SEC Form 6-K filing: up to $2.2 billion to resolve approximately 80,000 cases (93% of GSK's state court docket) through agreements with 10 plaintiff firms, with no admission of liability. GSK simultaneously disclosed a $70 million agreement in principle to resolve a qui tam complaint filed by Valisure under the False Claims Act, subject to DOJ approval. GSK recorded a £1.8 billion ($2.3 billion) charge in Q3 2024 covering the state court settlement, the qui tam settlement, and the remaining 7% of state court cases.
• Sanofi reportedly reached a settlement for approximately 4,000 claimants, according to Bloomberg reporting, but Sanofi has said the financial terms are confidential and has not confirmed that amount. Sanofi has also stated it "previously settled the majority of cases pending against it in state court without any concession of liability."
• Pfizer settled over 10,000 cases by May 2024, with the total amount undisclosed. Pfizer's Q2 2024 10-Q confirmed it had settled or entered agreements on "a substantial majority" of state court cases.
• Boehringer Ingelheim has not entered any global settlement. The company continues to litigate, carrying an 8-0 trial record and the April 2026 dismissal of the Delaware cases naming it as defendant.

The timing differential is the critical variable: GSK settled in October 2024, before the Delaware Supreme Court's July 2025 reversal. The $2.2 billion figure reflects settlement value under a procedural environment where Delaware's "liberal thrust" standard still favored plaintiffs.

The $2.2 billion GSK figure ranks among the largest pharmaceutical mass tort resolutions of the past decade. By comparison, Philips Respironics' April 2024 $1.1 billion settlement resolved CPAP recall personal injury claims through an MDL-track master settlement agreement. Zantac's resolution moved through state forums after the federal MDL dismissal, a structurally distinct path from the MDL-coordinated benchmark.

What the Zantac Daubert Litigation Means for Practitioners

The Zantac lawsuit record generates distinct implications across practice areas. The convergence of federal and Delaware state Daubert standards on expert admissibility has narrowed the viable forum for plaintiffs while clarifying defense strategy on settlement timing.

• For plaintiff counsel: Daubert exposure is now functionally equivalent across the federal MDL, Delaware, and Florida state systems. California remains a viable forum, where hung juries demonstrate that causation can survive to deliberation. Connecticut's bellwether track against Boehringer Ingelheim preserves an innovator liability theory for brand-name manufacturers.
• For defense counsel: A federal MDL Daubert order can propagate to state forums through the 2023 FRE 702 amendments, which reject presumptions favoring admissibility. Settlement-versus-litigate analysis must account for the possibility that subsequent rulings will vindicate defense positions: GSK's $2.2 billion settlement preceded its largest evidentiary victory by nine months.
• For coverage counsel: Pharmaceutical mass tort settlements without liability findings raise allocation and reservation-of-rights questions. The $70 million Valisure qui tam adds a False Claims Act exposure layer rarely seen in product liability. The brand-versus-generic preemption asymmetry, where generic manufacturers were dismissed on impossibility preemption while brand manufacturers faced full tort exposure, creates contribution and indemnification disputes across policy years.

Eleventh Circuit Decision and Connecticut Bellwethers

Three variables remain central. First, the Eleventh Circuit decision could reinforce or unsettle the current alignment between the federal MDL and Delaware on expert admissibility. Second, Boehringer Ingelheim's Connecticut bellwether track, with the first trials scheduled to begin March 14, 2028, keeps pressure on the one major defendant that has not pursued a global deal. Third, a residual slice of GSK's state docket remained outside the October 2024 agreement.

Strategic Implications for Pharmaceutical Mass Tort Practice

The Zantac lawsuit moved from Valisure's September 2019 citizen petition through MDL 2924's 341-page Daubert order to Delaware's full procedural alignment with the federal record. GSK's $2.2 billion state-court settlement, executed before the Delaware Supreme Court's July 2025 reversal, resolved approximately 80,000 cases without admission of liability.

The litigation reinforced the gatekeeping demands of post-2023 FRE 702 standards, where general causation analysis must connect the product itself rather than a degradation component to the alleged harm. Pharmaceutical product liability cases benefit from complete medication histories, pharmacy records, and structured medical chronologies prepared to withstand Daubert scrutiny at both consolidated and individual case levels. These foundations remain essential across analogous mass tort proceedings where causation theories must survive evidentiary review.

For additional pharmaceutical MDL analysis, see the Ozempic federal litigation coverage.